bluebird bio, Inc. (BLUE) Given “Outperform” Rating at Leerink Swann
Leerink Swann reaffirmed their outperform rating on shares of bluebird bio, Inc. (NASDAQ:BLUE) in a research report report published on Saturday. They currently have a $120.00 target price on the biotechnology company’s stock.
BLUE has been the topic of several other reports. Cowen and Company reaffirmed an outperform rating on shares of bluebird bio in a report on Thursday, August 31st. Wells Fargo & Company reiterated an outperform rating and set a $158.00 price objective (up from $134.00) on shares of bluebird bio in a research note on Tuesday, September 5th. Wedbush reissued an outperform rating and set a $135.00 price objective (up from $121.00) on shares of bluebird bio in a report on Friday, September 1st. Cantor Fitzgerald set a $37.00 price objective on shares of bluebird bio and gave the stock a sell rating in a report on Monday, June 5th. Finally, BTIG Research downgraded shares of bluebird bio from a buy rating to a neutral rating and boosted their target price for the stock from $37.05 to $108.25 in a research report on Friday, June 30th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and thirteen have given a buy rating to the company. bluebird bio currently has an average rating of Hold and a consensus price target of $109.61.
bluebird bio (BLUE) opened at 127.55 on Friday. bluebird bio has a one year low of $37.05 and a one year high of $143.50. The firm’s market capitalization is $5.81 billion. The company has a 50-day moving average price of $118.73 and a 200-day moving average price of $100.09.
bluebird bio (NASDAQ:BLUE) last announced its earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.66) by ($0.07). The business had revenue of $16.70 million during the quarter, compared to analyst estimates of $6.29 million. bluebird bio had a negative net margin of 1,080.59% and a negative return on equity of 32.19%. The business’s revenue for the quarter was up 977.4% on a year-over-year basis. During the same period in the previous year, the company earned ($1.59) earnings per share. On average, equities research analysts anticipate that bluebird bio will post ($6.77) EPS for the current year.
In other bluebird bio news, Director John Maraganore sold 18,868 shares of the business’s stock in a transaction dated Thursday, September 14th. The shares were sold at an average price of $131.21, for a total transaction of $2,475,670.28. Following the completion of the transaction, the director now directly owns 24,711 shares of the company’s stock, valued at approximately $3,242,330.31. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Philip D. Gregory sold 2,250 shares of the business’s stock in a transaction dated Thursday, July 6th. The shares were sold at an average price of $103.83, for a total transaction of $233,617.50. Following the transaction, the insider now directly owns 33,734 shares of the company’s stock, valued at $3,502,601.22. The disclosure for this sale can be found here. Insiders have sold 128,829 shares of company stock valued at $15,480,499 in the last 90 days. Insiders own 3.90% of the company’s stock.
Large investors have recently made changes to their positions in the business. FMR LLC raised its holdings in shares of bluebird bio by 9.6% during the second quarter. FMR LLC now owns 6,713,949 shares of the biotechnology company’s stock valued at $705,301,000 after buying an additional 587,236 shares during the last quarter. Capital Research Global Investors boosted its position in shares of bluebird bio by 9.9% during the second quarter. Capital Research Global Investors now owns 5,483,117 shares of the biotechnology company’s stock worth $576,001,000 after buying an additional 493,072 shares during the period. Baillie Gifford & Co. boosted its position in shares of bluebird bio by 3.8% during the second quarter. Baillie Gifford & Co. now owns 5,400,658 shares of the biotechnology company’s stock worth $567,339,000 after buying an additional 196,025 shares during the period. Vanguard Group Inc. boosted its position in shares of bluebird bio by 10.7% during the second quarter. Vanguard Group Inc. now owns 3,559,102 shares of the biotechnology company’s stock worth $373,884,000 after buying an additional 343,856 shares during the period. Finally, BlackRock Inc. boosted its position in shares of bluebird bio by 4.3% during the second quarter. BlackRock Inc. now owns 3,320,329 shares of the biotechnology company’s stock worth $348,801,000 after buying an additional 138,141 shares during the period.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.